ArticleBMJ (Clinical research ed.)2005
Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.
Article in BMJ (Clinical research ed.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis.Drugs · 2012 · on this mapPooled it
- Pooled it
- Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study.European journal of clinical pharmacology · 2009Pooled it
- The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.BMJ (Clinical research ed.) · 2009 · on this mapPooled it
- Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients.BMJ (Clinical research ed.) · 2005Trial
- Methods Applied to Assess Real-World Effectiveness of Drugs: A Scoping Review.Pharmacology research & perspectives · 2026Article
- Statin-related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality.British journal of clinical pharmacology · 2022Article
- Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis.Journal of health economics and outcomes research · 2022Article
- Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.Canadian family physician Medecin de famille canadien · 2017Article
- Using electronic health records to predict costs and outcomes in stable coronary artery disease.Heart (British Cardiac Society) · 2016Article
- Relationship between Statin Utilization and Socioeconomic Deprivation in Hungary.Frontiers in pharmacology · 2016Article
- Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data.Clinical epidemiology · 2016Article
- Do Statins Reduce the Health and Health Care Costs of Obesity?PharmacoEconomics · 2015Article
- Article
- Statin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman.Oman medical journal · 2014Article
- Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland.BMJ open · 2014Article
- Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database.Pharmacoepidemiology and drug safety · 2014Article
- Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study.BMC cardiovascular disorders · 2011Article
- An overview of lipid abnormalities in patients with inflammatory bowel disease.Annals of gastroenterology · 2011Review
- Osteoporosis therapies: evidence from health-care databases and observational population studies.Calcified tissue international · 2010Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the social and demographic profiles of patients who receive statin treatment after myocardial infarction and patients included in randomised trials. To estimate the effect of statin use in community based patients on subsequent all cause mortality and cardiovascular recurrence, contrasting effects with trial patients.
designObservational cohort study using a record linkage database.
settingTayside, Scotland (population size and characteristics: about 400,000, mixed urban and rural). SUBJECTS: 4892 patients were discharged from hospital after their first myocardial infarction between January 1993 and December 2001. 2463 (50.3%) were taking statins during an average follow-up of 3.7 years (3.1% in 1993 and 62.9% in 2001).
main outcome measuresAll cause mortality and recurrence of cardiovascular events.
results319 deaths occurred in the statin treated group (age adjusted rate 4.1 per 100 person years, 95% confidence interval 3.2 to 4.9), and 1200 in the statin untreated group (12.7 per 100 person years, 11.1 to 14.3). More older people and women were represented in the population of patients treated with statins than among those recruited into clinical trials (mean age 67.8 v 59.8; women 39.6% v 16.9%, respectively). The effects of statins in routine clinical practice were consistent with, and similar to, those reported in clinical trials (adjusted hazard ratio for all cause mortality 0.69, 95% confidence interval 0.59 to 0.80; adjusted hazard ratio for cardiovascular recurrence 0.82, 0.71 to 0.95).
conclusionsThe community effectiveness of statins in those groups that were not well represented in clinical trials was similar to the efficacy of statins in these trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.